Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

BACKGROUND: Limited data are available on the concordance between multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for minimal residual disease (MRD) detection in a large trial for multiple myeloma (MM) patients. METHODS: MRD was explored in the FORTE trial for transplant-eli...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Stefania, Genuardi, Elisa, Paris, Laura, D'Agostino, Mattia, Rogers, Jennifer, Rota-Scalabrini, Delia, Jacob, Allison P., Patriarca, Francesca, Luppi, Mario, Bertazzoni, Paola, Velluti, Cristina, Capra, Andrea, Saraci, Elona, Rossi, Marco, Allegra, Alessandro, Mina, Roberto, Gentile, Massimo, Kirsch, Ilan R., Belotti, Angelo, Cavo, Michele, Bruno, Benedetto, Musto, Pellegrino, Boccadoro, Mario, Zamagni, Elena, Gay, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314153/
https://www.ncbi.nlm.nih.gov/pubmed/37396800
http://dx.doi.org/10.1016/j.eclinm.2023.102016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314153/
https://www.ncbi.nlm.nih.gov/pubmed/37396800
http://dx.doi.org/10.1016/j.eclinm.2023.102016

Ejemplares similares